Application of Sodium Bicarbonate Ringer's Solution in Laparoscopic Hepatectomy

The Application of Sodium Bicarbonate Ringer's Solution on Perioperative Lactic Acid Concentration and Early Recovery Quality in Patients Undergoing Laparoscopic Hepatectomy

Compared the effects of Sodium bicarbonate Ringer's solution and lactate Ringer's solution on the internal environment and hemodynamics of patients during laparoscopic liver resection, to observe the application prospect of sodium bicarbonate Ringer's solution in Laparoscopic hepatectomy.

The study was a single-center prospective randomized controlled study. A total of 100 patients undergoing laparoscopic hepatectomy under general anesthesia were randomly divided into 2 groups: Group A, sodium bicarbonate Ringer's solution group(n=50); Group B, Lactate Ringer's solution group (intraoperative crystal fluid dilatation was lactate ringer's injection, n=50); Collect patients' arterial blood gas, blood pressure, heart rate, peripheral vascular resistance, heart rate, blood vessels, the active drug usage, 5% sodium bicarbonate injection usage, inflammation factors, transaminase, creatinine, etc. with the point of preoperative (T0), during liver specimens resected(T1), after liver specimens resected(T2), and the end of surgery (T3). Then statistical analysis and observe the application prospect of sodium bicarbonate Ringer's injection in Laparoscopic hepatectomy.

Sodium bicarbonate Ringer's solution was used in Group A as intraoperative intravenous fluids. Lactate Ringer's solution was used in Group B as intraoperative intravenous fluids.

From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 month.

From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 month.

From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 month.

From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 month.

From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 month.

15-item quality of recovery scale scores. the minimum value is 0 and maximum value is 150, and whether higher scores mean a better outcome.

Inclusion Criteria: ≥18 years old, patients who plan to undergoing laparoscopic hepatectomy ; Willing to sign informed consent. Exclusion Criteria: age <18 years pregnancy active cardiac conditions (unstable coronary syndromes, decompensated heart failure, significant arrhythmias, severe valvular disease, history of congestive heart failure) history of significant cerebrovascular disease restrictive or obstructive pulmonary disease uncontrolled hypertension renal dysfunction (glomerular filtration rate <60 mL/min), evidence of hepatic metabolic disorder (bilirubin >35 mmol/L) presence of active infection